Literature DB >> 2229562

Proton MR spectroscopy of the brain in infants.

C J Peden1, F M Cowan, D J Bryant, J Sargentoni, I J Cox, D K Menon, D G Gadian, J D Bell, L M Dubowitz.   

Abstract

Proton magnetic resonance spectroscopy (MRS) was used to study the brain of 2 normal and 15 abnormal infants aged from 33 weeks postmenstrual age (PMA) to 14 months postnatal age. Eleven of the infants were examined on at least two occasions. The principal clinical diagnoses in the abnormal infants were perinatal ischemic and hemorrhagic brain injury. All proton spectra demonstrated peaks that were assigned to N-acetylaspartate (NAA), choline containing compounds (Cho), and creatine plus phosphocreatine (Cr). The NAA/Cho and NAA/Cr ratios increased with age, while the Cho/Cr ratio decreased with age in the majority of infants. The NAA/Cho ratio was generally lower in abnormal infants, but the difference was not apparent before 40 weeks (PMA). This ratio was lowest in infants with the severest degree of neurological abnormality. Proton and phosphorus MRS was compared in seven infants. In those with severe brain lesions, early phosphorus spectra were abnormal. On follow-up the phosphorus spectra became normal, but the proton spectra showed persistently low NAA/Cho and NAA/Cr ratios. Proton MRS provides new information that may be complementary to phosphorus MRS in the diagnosis and monitoring of brain development in normal and neurologically damaged infants.

Entities:  

Mesh:

Year:  1990        PMID: 2229562     DOI: 10.1097/00004728-199011000-00004

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  16 in total

1.  Localized proton magnetic resonance spectroscopy of a cerebellar tumor in a two-year-old child.

Authors:  B Wilken; G Helms; H J Christen; J Behnke; J Frahm; F Hanefeld
Journal:  Childs Nerv Syst       Date:  1996-10       Impact factor: 1.475

Review 2.  Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making.

Authors:  Alexander Lin; Brian D Ross; Kent Harris; Willis Wong
Journal:  NeuroRx       Date:  2005-04

Review 3.  MRI evaluation and safety in the developing brain.

Authors:  Shannon Tocchio; Beth Kline-Fath; Emanuel Kanal; Vincent J Schmithorst; Ashok Panigrahy
Journal:  Semin Perinatol       Date:  2015-03-03       Impact factor: 3.300

4.  Developmental delay in children: assessment with proton MR spectroscopy.

Authors:  Christopher G Filippi; Aziz M Uluğ; Michael D F Deck; Robert D Zimmerman; Linda A Heier
Journal:  AJNR Am J Neuroradiol       Date:  2002-05       Impact factor: 3.825

5.  Reference values for long echo time MR spectroscopy in healthy adults.

Authors:  Yair Safriel; Marlyanne Pol-Rodriguez; Edward J Novotny; Douglas L Rothman; Robert K Fulbright
Journal:  AJNR Am J Neuroradiol       Date:  2005 Jun-Jul       Impact factor: 3.825

6.  Increased detectability of alpha brain glutamate/glutamine in neonatal hypoxic-ischemic encephalopathy.

Authors:  Y Pu; Q F Li; C M Zeng; J Gao; J Qi; D X Luo; S Mahankali; P T Fox; J H Gao
Journal:  AJNR Am J Neuroradiol       Date:  2000-01       Impact factor: 3.825

Review 7.  Patterns of neonatal hypoxic-ischaemic brain injury.

Authors:  Linda S de Vries; Floris Groenendaal
Journal:  Neuroradiology       Date:  2010-06       Impact factor: 2.804

8.  Magnetic resonance spectroscopy in pediatric neuroradiology: clinical and research applications.

Authors:  Ashok Panigrahy; Marvin D Nelson; Stefan Blüml
Journal:  Pediatr Radiol       Date:  2009-11-24

Review 9.  What might be the impact on neurology of the analysis of brain metabolism by in vivo magnetic resonance spectroscopy?

Authors:  J Vion-Dury; D J Meyerhoff; P J Cozzone; M W Weiner
Journal:  J Neurol       Date:  1994-05       Impact factor: 4.849

10.  Hypoxic encephalopathy after near-drowning studied by quantitative 1H-magnetic resonance spectroscopy.

Authors:  R Kreis; E Arcinue; T Ernst; T K Shonk; R Flores; B D Ross
Journal:  J Clin Invest       Date:  1996-03-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.